Labcorp Drug Development Inc - Company Profile
Powered by 
All the sales intelligence you need on Labcorp Drug Development Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Labcorp Drug Development Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Labcorp Drug Development Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Labcorp Drug Development Inc (Labcorp), formerly Covance Inc, is a contract research company that offers drug development and manufacturing services. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, informatics, clinical testing, clinical development, commercialization, and manufacturing support, among others. It offers solutions in various therapeutic areas such as cardiovascular; diabetes, endocrinology and nephrology; immuno-oncology; infectious diseases; inflammation; neuroscience; non-alcoholic steatohepatitis; oncology; rare disease and orphan drugs; and pediatrics. Labcorp also offers laboratory testing services for agrochemical and chemical industries. It operates in the US, Europe, Latin America, Africa, and Asia-Pacific. The company operates as a subsidiary of Laboratory Corp of America Holdings. Labcorp is headquartered in Burlington, North Carolina, the US.
Headquarters
United States of America
Address
531 S. Spring Road, Burlington, North Carolina, 46214
Website
www.drugdevelopment.labcorp.com
Telephone
1 336 5845171
Industry
Pharmaceuticals and Healthcare
Labcorp Drug Development Inc premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Research | FSPx |
| Lead Optimization | TeleCenter |
| Analysis Services | LabLink |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In April, the company announced the launchof its pTau-217/Beta Amyloid 42 Ratio, a new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. |
| 2024 | Corporate Changes/Expansions | In September, the company announced the expansion of its molecular bioanalytical laboratory in Greenfield, Indiana. |
| 2023 | Contracts/Agreements | In March, the company entered into an agreement to acquire the assets of Enzo Biochem, Inc.'s Clinical Laboratory division. |
Competitor Comparison
| Key Parameters | Labcorp Drug Development Inc | IQVIA Holdings Inc | ICON Plc | Frontage Holdings Corp | ClinOne Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Ireland | United States of America | United States of America |
| City | Burlington | Durham | Dublin | Exton | Needham |
| State/Province | North Carolina | North Carolina | Dublin | Pennsylvania | Massachusetts |
| No. of Employees | - | 93,000 | 40,100 | 1,523 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sandra D. Van Der Vaart | President; Secretary | Senior Management | - | - |
| Robert S. Pringle | Treasurer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer